Cytokine Storm score (CSs) in COVID-19 Patients Smokers at Dr. Saiful Anwar Malang
DOI:
https://doi.org/10.36408/mhjcm.v10i2.902Keywords:
cytokine storm, Covid-19, Cytokine Storm score (CSs), smokerAbstract
Background: After 3 years of the COVID-19 pandemic, its escalation is still causing a critical global health problem. Cytokine storm is a severe complication of COVID-19, and smoking is a risk factor for death. The prevalence of smoking in Indonesia is very high, but there is still little research on the effect of smoking on the occurrence of cytokine storms. The Cytokines Storm Score (CSs) is a quick and simple method for detecting cytokine storms early by utilizing D-dimer, lactate dehydrogenase (LDH), ferritin, and C-reactive protein (CRP) parameters.
Objective: To evaluate CSs in COVID-19 patients smokers
Methods: Retrospective analysis of 120 confirmed COVID-19 patients in November 2020–2021, divided into 2 groups (60 smokers and nonsmokers), male, without comorbidities. analysis using Chi-square and Mann-Whitney. Prior to the CSs examination, lymphopenia is required. CSs were positive if at least two of the D-dimer, LDH, or ferritin levels were elevated. The CRP level is measured if there is an increase in only one of these values. Elevated CRP, lymphopenia, and impaired D-Dimer, LDH, or ferritin will result in positive CSs.
Results: CSs were significantly higher in smokers than non-smokers (54.5% vs. 45.5%, p = 0.024). D-dimer and CRP levels were significantly higher in smokers than non-smokers (1620 ng/mL vs. 1002.5 ng/mL, p = 0.001; and 13.8 mg/dL vs. 7.75 mg/dL, p = 0.001). Lower LDH and higher ferritin levels were not significant in smokers compared to nonsmokers (405.5 IU/L vs. 418 IU/L, p = 0.160; and 886.65 ng/mL vs. 790.5 ng/mL, p = 0.203).
Conclusion: Cytokines Storm scores (CSs) increased significantly in COVID-19 patients who smoked, D-dimer and CRP levels were significantly higher in smoking COVID-19 patients compared to non-smokers
Downloads
References
1. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Wicaksono PE, et, al. 2020. Pedoman Tatalaksana COVID-19.
2. Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. Indian journal of clinical biochemistry. 2015 Jan;30(1):11-26.
3. Kashyap VK, Dhasmana A, Massey A, Kotnala S, Zafar N, Jaggi M, Yallapu MM, Chauhan SC. Smoking and COVID-19: adding fuel to the flame. International journal of molecular sciences. 2020 Sep 9;21(18):6581.
4. Listyoko AS, Djajalaksana S, Astuti T. Hubungan Merokok dengan Derajat Keparahan dan Mortalitas Pasien COVID-19 Rawat Inap di RS Saiful Anwar Malang. Medica Hospitalia: Journal of Clinical Medicine. 2020 Aug 28;7(1A):137-43.
5. Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, EA B. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC Basic Transl Sci. 2020; 518–536.
6. Cappanera S, Palumbo M, Kwan SH, Priante G, Martella LA, Saraca LM, Sicari F, Vernelli C, Di Giuli C, Andreani P, Mariottini A. When does the cytokine storm begin in COVID-19 patients? A quick score to recognize it. Journal of clinical medicine. 2021 Jan 15;10(2):297.
7. Silva AL, Moreira JC, Martins SR. COVID-19 and smoking: a high-risk association. Cadernos de Saúde Pública. 2020 May 18;36:e00072020.
8. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of pharmaceutical analysis. 2020 Apr 1;10(2):102-8.
9. Raddam QN, Zeidan MM, Asaad NK, Abdulrahman MA. Smoking effects on blood antioxidants level: lactate dehydrogenase, catalase, superoxide dismutase and glutathione peroxidase in university students. Journal of Clinical & Experimental Pathology. 2017;7(6):2161-0681.
10. Pappas RS. Toxic elements in tobacco and in cigarette smoke: inflammation and sensitization. Metallomics. 2011 Nov;3(11):1181-98.
11. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic advances in respiratory disease. 2020 Jun;14:1753466620937175.
12. Elfadil GA, Elfaki EM, Madani SO, Abdalhabib EK, Elmugadam A. High-Sensitive C-reactive Protein and Atherogenic Lipid Levels in a Group of University Students with Habitual Smoking. Biomedical and Pharmacology Journal. 2020 Sep 25;13(03):1489-94.
13. KEMENKES RI. Hasil Riset Kesehatan Dasar Tahun 2018. Kementrian Kesehatan RI, 2018;53(9), 1689–1699.
14. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. American journal of respiratory and critical care medicine. 2020 Jun 15;201(12):1557-9.
15. Ibañez C, Perdomo J, Calvo A, Ferrando C, Reverter JC, Tassies D, Blasi A. High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there?. Journal of thrombosis and thrombolysis. 2021 Feb;51(2):308-12.
16. Zhang T, Huang WS, Guan W, Hong Z, Gao J, Gao G, Wu G, Qin YY. Risk factors and predictors associated with the severity of COVID-19 in China: a systematic review, meta-analysis, and meta-regression. Journal of thoracic disease. 2020 Dec;12(12):7429.
17. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of infection. 2020 Aug 1;81(2):e16-25.
18. Lee CH, Goag EK, Lee SH, Chung KS, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Song JH. Association of serum ferritin levels with smoking and lung function in the Korean adult population: analysis of the fourth and fifth Korean National Health and Nutrition Examination Survey. International journal of chronic obstructive pulmonary disease. 2016;11:3001.
19. Khinda J, Janjua NZ, Cheng S, van den Heuvel ER, Bhatti P, Darvishian M. Association between markers of immune response at hospital admission and COVID‐19 disease severity and mortality: A meta‐analysis and meta‐regression. Journal of medical virology. 2021 Feb;93(2):1078-98.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2023 Resti Fitriani Yuliawati, Tri Wahju Astuti, Yani Jane Sugiri
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
